1996
DOI: 10.1159/000462051
|View full text |Cite
|
Sign up to set email alerts
|

Safety of Blood Products Derived from Plasma Pools: The Positive Impact of Anti-HCV Screening on the Quality of Such Products

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

1998
1998
2000
2000

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 4 publications
0
2
0
Order By: Relevance
“…The Blood Transfusion Service of Baden-Württemberg (420,00 donations/year) introduced, in January 1997, the screening of plasma minipools (n = 96) by PCR for detection of HBV, HCV and HIV nucleic acids. From a previous study on larger plasma pools (n = 5,000) derived from this blood donor population, it was known that the introduction of anti-HCV screening had a positive effect on the viral safety of these pools [3]. PCR screening was introduced stepwise, beginning with the testing of blood donations collected by the blood transfusion institute in Ulm (~800 donations/day) in January 1997.…”
Section: Introductionmentioning
confidence: 99%
“…The Blood Transfusion Service of Baden-Württemberg (420,00 donations/year) introduced, in January 1997, the screening of plasma minipools (n = 96) by PCR for detection of HBV, HCV and HIV nucleic acids. From a previous study on larger plasma pools (n = 5,000) derived from this blood donor population, it was known that the introduction of anti-HCV screening had a positive effect on the viral safety of these pools [3]. PCR screening was introduced stepwise, beginning with the testing of blood donations collected by the blood transfusion institute in Ulm (~800 donations/day) in January 1997.…”
Section: Introductionmentioning
confidence: 99%
“…The risk associated with the transfusion of blood and blood components has been significantly re‐ duced by the screening of donors and the testing of blood components for specific pathogens 1 . There are, however, several limitations to screening: 1) current tests may miss certain infectious units, particularly during the early phase of infection before seroconversion; 2) effective tests are not available for all known pathogens; 3) newly emerging viruses or microorganisms cannot be detected 2 ; and 4) the marginal benefit‐to‐cost ratio becomes prohibitively high for new tests 3 .…”
mentioning
confidence: 99%